FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088717396> ?p ?o ?g. }

• W3088717396 endingPage "299" @default.
• W3088717396 startingPage "287" @default.
• W3088717396 abstract "Objective To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow upright vital capacity (SVC) of ≥60% were randomized 1:1:1:1 to reldesemtiv 150, 300, or 450 mg twice daily (bid) or placebo; active treatment was 12 weeks with 4-week follow-up. Primary endpoint was change in percent predicted SVC at 12 weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) and muscle strength mega-score. Results: Patients (N = 458) were enrolled; 85% completed 12-week treatment. The primary analysis failed to reach statistical significance (p = 0.11); secondary endpoints showed no statistically significant effects (ALSFRS-R, p = 0.09; muscle strength mega-score, p = 0.31). Post hoc analyses pooling all active reldesemtiv-treated patients compared against placebo showed trends toward benefit in all endpoints (progression rate for SVC, ALSFRS-R, and muscle strength mega-score (nominal p values of 0.10, 0.01 and 0.20 respectively)). Reldesemtiv was well tolerated, with nausea and fatigue being the most common side effects. A dose-dependent decrease in estimated glomerular filtration rate was noted, and transaminase elevations were seen in approximately 5% of patients. Both hepatic and renal abnormalities trended toward resolution after study drug discontinuation. Conclusions: Although the primary efficacy analysis did not demonstrate statistical significance, there were trends favoring reldesemtiv for all three endpoints, with effect sizes generally regarded as clinically important. Tolerability was good; modest hepatic and renal abnormalities were reversible. The impact of reldesemtiv on patients with ALS should be assessed in a pivotal Phase 3 trial. (ClinicalTrials.gov Identifier: NCT03160898)" @default.
• W3088717396 created "2020-10-01" @default.
• W3088717396 creator A5001304246 @default.
• W3088717396 creator A5003112399 @default.
• W3088717396 creator A5004383772 @default.
• W3088717396 creator A5005609900 @default.
• W3088717396 creator A5009864431 @default.
• W3088717396 creator A5012854074 @default.
• W3088717396 creator A5014335916 @default.
• W3088717396 creator A5015861848 @default.
• W3088717396 creator A5020442716 @default.
• W3088717396 creator A5021958762 @default.
• W3088717396 creator A5022326820 @default.
• W3088717396 creator A5029639314 @default.
• W3088717396 creator A5030609927 @default.
• W3088717396 creator A5030730290 @default.
• W3088717396 creator A5030742327 @default.
• W3088717396 creator A5031078066 @default.
• W3088717396 creator A5032745219 @default.
• W3088717396 creator A5032923167 @default.
• W3088717396 creator A5036838632 @default.
• W3088717396 creator A5038664397 @default.
• W3088717396 creator A5039905544 @default.
• W3088717396 creator A5040375788 @default.
• W3088717396 creator A5040381323 @default.
• W3088717396 creator A5043129865 @default.
• W3088717396 creator A5045343579 @default.
• W3088717396 creator A5046488842 @default.
• W3088717396 creator A5048588036 @default.
• W3088717396 creator A5049803861 @default.
• W3088717396 creator A5051053936 @default.
• W3088717396 creator A5051877073 @default.
• W3088717396 creator A5052581382 @default.
• W3088717396 creator A5052880954 @default.
• W3088717396 creator A5053813711 @default.
• W3088717396 creator A5056240044 @default.
• W3088717396 creator A5058244935 @default.
• W3088717396 creator A5060424866 @default.
• W3088717396 creator A5063229609 @default.
• W3088717396 creator A5063719862 @default.
• W3088717396 creator A5064714121 @default.
• W3088717396 creator A5066514556 @default.
• W3088717396 creator A5067234869 @default.
• W3088717396 creator A5068656707 @default.
• W3088717396 creator A5070233617 @default.
• W3088717396 creator A5073608742 @default.
• W3088717396 creator A5074064047 @default.
• W3088717396 creator A5079949666 @default.
• W3088717396 creator A5080276406 @default.
• W3088717396 creator A5080435150 @default.
• W3088717396 creator A5080553026 @default.
• W3088717396 creator A5080741844 @default.
• W3088717396 creator A5082774982 @default.
• W3088717396 creator A5087381556 @default.
• W3088717396 creator A5087544782 @default.
• W3088717396 date "2020-09-24" @default.
• W3088717396 modified "2023-10-13" @default.
• W3088717396 title "A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS" @default.
• W3088717396 cites W1937420369 @default.
• W3088717396 cites W1979709260 @default.
• W3088717396 cites W1984218351 @default.
• W3088717396 cites W1986324725 @default.
• W3088717396 cites W2013284164 @default.
• W3088717396 cites W2052940055 @default.
• W3088717396 cites W2056007742 @default.
• W3088717396 cites W2056132964 @default.
• W3088717396 cites W2099449365 @default.
• W3088717396 cites W2130289530 @default.
• W3088717396 cites W2139560421 @default.
• W3088717396 cites W2144536780 @default.
• W3088717396 cites W2147955864 @default.
• W3088717396 cites W2161938104 @default.
• W3088717396 cites W2302268132 @default.
• W3088717396 cites W2616124858 @default.
• W3088717396 cites W2737602336 @default.
• W3088717396 cites W2769572735 @default.
• W3088717396 cites W2770952827 @default.
• W3088717396 cites W2773298812 @default.
• W3088717396 doi "https://doi.org/10.1080/21678421.2020.1822410" @default.
• W3088717396 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8117790" @default.
• W3088717396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32969758" @default.
• W3088717396 hasPublicationYear "2020" @default.
• W3088717396 type Work @default.
• W3088717396 sameAs 3088717396 @default.
• W3088717396 citedByCount "38" @default.
• W3088717396 countsByYear W30887173962020 @default.
• W3088717396 countsByYear W30887173962021 @default.
• W3088717396 countsByYear W30887173962022 @default.
• W3088717396 countsByYear W30887173962023 @default.
• W3088717396 crossrefType "journal-article" @default.
• W3088717396 hasAuthorship W3088717396A5001304246 @default.
• W3088717396 hasAuthorship W3088717396A5003112399 @default.
• W3088717396 hasAuthorship W3088717396A5004383772 @default.
• W3088717396 hasAuthorship W3088717396A5005609900 @default.
• W3088717396 hasAuthorship W3088717396A5009864431 @default.
• W3088717396 hasAuthorship W3088717396A5012854074 @default.
• W3088717396 hasAuthorship W3088717396A5014335916 @default.
• W3088717396 hasAuthorship W3088717396A5015861848 @default.

• next